Affinity Asset Advisors, LLC Zentalis Pharmaceuticals, Inc. Transaction History

Affinity Asset Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $2.02 Million - $3.17 Million	100,000 Added 142.86%	170,000 $3.68 Million
Q2 2022 Aug 12, 2022	SELL	$17.91 - $52.25 $2.46 Million - $7.18 Million	-137,500 Reduced 66.27%	70,000 $1.97 Million
Q1 2022 May 13, 2022	BUY	$41.58 - $80.89 $3.74 Million - $7.28 Million	90,000 Added 76.6%	207,500 $9.57 Million
Q4 2021 Feb 11, 2022	BUY	$66.92 - $84.79 $2.68 Million - $3.39 Million	40,000 Added 51.61%	117,500 $9.88 Million
Q3 2021 Nov 12, 2021	SELL	$46.83 - $73.5 $3.04 Million - $4.77 Million	-64,918 Reduced 45.58%	77,500 $5.17 Million
Q2 2021 Aug 13, 2021	BUY	$37.41 - $62.25 $2.43 Million - $4.04 Million	64,918 Added 83.77%	142,418 $7.58 Million
Q1 2021 May 14, 2021	BUY	$35.69 - $52.72 $2.77 Million - $4.09 Million	77,500 New	77,500 $3.36 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.